Jeil Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Jeil Pharmaceutical makes prescription and over-the-counter medicines used by patients and healthcare providers in South Korea.
Its products are supplied through hospitals, clinics, and pharmacies. The company is listed on KOSPI, South Korea's main stock exchange, and remains profitable despite a recent decline in revenue.
Summary is AI-generated and may contain errors · figures from DART filings
Jeil Pharmaceutical in five facts
What does Jeil Pharmaceutical do?
Jeil Pharmaceutical makes prescription and over-the-counter medicines used by patients and healthcare providers in South Korea.
Where is Jeil Pharmaceutical listed and in which sector?
Jeil Pharmaceutical (Korean name: 제일약품) trades under KRX code 271980 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Jeil Pharmaceutical?
Its market capitalisation was US$102M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Jeil Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Jeil Pharmaceutical reported revenue of US$428.1M, operating profit of US$15.6M and net income of US$24.2M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 19.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Treasury share disposal: results reportTreasury Shares · Feb 26
- Material event report (treasury share disposal)
Jeil Pharmaceutical disclosed a plan to sell treasury shares worth US$1.49M, about 1.5% of its market value.
Treasury Shares · Feb 25 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Jeil Pharmaceutical reported consolidated results for FY2025: revenue of US$392M (−19.6% year on year), operating profit of US$14.3M (from a loss a year earlier) and net income of US$22.2M (from a loss a year earlier).
Earnings · Feb 23